Rosenwald A, Bens S, Advani R, et al. - Given that nearly 10% of diffuse large B-cell lymphomas (DLBCLs) have MYC rearrangement (MYC-R), which has been related to poor prognosis in many investigations, and a possible influence of the MYC partner gene (immunoglobulin [IG] or a non-IG gene) on the prognostic impact of MYC-R has been suggested, therefore, researchers sought to confirm the prognostic significance of MYC-R (single-, double-, and triple-hit status) in DLBCL within the context of the MYC partner gene, using an extensive cohort of patients through the Lunenburg Lymphoma Biomarker Consortium. Participants were obtained from large prospective trials and patient registries in Europe and North America and included patients having histologically proved DLBCL morphology uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy or the like. Findings revealed the negative prognostic influence of MYC-R in DLBCL, largely seen in those with MYC double hit/triple-hit disease in which MYC is translocated to an IG partner. This influence was limited to the first 2 years postdiagnosis. Using diagnostic strategies to recognize this high-risk cohort, as well as refining further risk-adjusted therapeutic approaches, was recommended.